‹
›
This content requires a premium subscription.
Please
log in
or
subscribe
to continue.
<iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/6753154/height/506/theme/custom/thumbnail/yes/direction/backward/render-playlist/no/custom-color/d4bf69/" height="506" width="100%" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe>
The Beacon
Small Trial Shows Big Risks of Giving First Line Pembrolizumab to EGFR Mutation-Positive Patients, Even with High Tumor PD-L1 Expression (BMIC-042)
30
00:00:00
/ 00:07:12
30
